Trial Profile
A Retrospective,Cohort study to assess treatment patterns in patients with Neovascular age related Macular Degeneration treated with Ranibizumab or Alibercept
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Nov 2016
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary) ; Ranibizumab (Primary)
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- 17 Nov 2016 New trial record
- 02 Nov 2016 Results presented at the 19th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research